Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 22, 2017 06:00 ET | Source: Gemphire Therapeutics Inc.

Gemphire to Present at the Piper Jaffray and LD Micro Investor Conferences

LIVONIA, Mich., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
November 13, 2017 13:30 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial Results

Gemcabene reduced LDL-C by 20% and hsCRP by 53% when added to moderate intensity statin therapy In cardiometabolic patients gemcabene improves atherogenic burden and reduces inflammation LIVONIA,...
October 23, 2017 08:00 ET | Source: Gemphire Therapeutics Inc.

Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017

Data Support Clinical Evaluation of Gemcabene as a Potential Treatment For NAFLD/NASH Clinical Trial in NAFLD/NASH Planned to Begin 4Q-2017 LIVONIA, Mich., Oct. 23, 2017 (GLOBE NEWSWIRE) --...
September 25, 2017 09:00 ET | Source: Gemphire Therapeutics

Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit

COBALT-1 results show significant LDL-C lowering for FH patients, including a mean reduction in LDL-C of 39% in the HeFH population Gemcabene demonstrates novel mechanism to significantly lower LDL-C...
September 19, 2017 16:01 ET | Source: Gemphire Therapeutics

Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development

New analysis of data shows clinically meaningful reductions in LDL-C and hsCRP across multiple trials and confirms support to advance gemcabene into Phase 3 End of Phase 2 meetings planned for early...
September 18, 2017 08:00 ET | Source: Gemphire Therapeutics

Gemphire to Present at Cantor Fitzgerald Global Healthcare Conference on September 26 in New York

LIVONIA, Mich., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
September 14, 2017 16:36 ET | Source: Gemphire Therapeutics

Gemphire to Host Investor Conference Call to Discuss Future Development Plans for Gemcabene

Company plans to advance gemcabene into Phase 3 development Conference call at 4:30 pm ET on September 19 LIVONIA, Mich., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc....
August 14, 2017 06:00 ET | Source: Gemphire Therapeutics

Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update

Gemcabene Successful in Phase 2 COBALT-1 HoFH Trial Gemcabene Hits Primary Endpoint in Phase 2 ROYAL-1 Hypercholesterolemia Trial LIVONIA, Mich., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Gemphire...
August 07, 2017 10:00 ET | Source: Gemphire Therapeutics

Gemphire to Present at the Canaccord Genuity Growth Conference 2017

LIVONIA, Mich., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
August 07, 2017 06:00 ET | Source: Gemphire Therapeutics

Gemphire Announces Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients

Gemcabene met the primary endpoint and demonstrated a statistically significant lowering in LDL-C Company to host conference call at 8:00 am ET, Monday, August 7, 2017 LIVONIA, Mich., Aug. 07,...